BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04294810 (Tiragolumab in Non-Small Cell Lung Cancer): BVCT ex-ante prediction vs. reported outcome

On 18 Jan 2024, BioinvestGPT's BVCT predicted technical failure and commercial failure for this trial. The 26 Nov 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04294810
Acronym
SKYSCRAPER-01
Drug Name
Tiragolumab
Drug MoA
anti-TIGIT mAb inhibitor
Drug Modality
monoclonal antibody
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Non-Small Cell Lung Cancer
Human Patients
620
Sponsor
Roche Group
Phase
Phase 3

Prediction of , index 1429

Prospective Prediction
Prediction Index
1429
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient additive clinical benefit in OS)
Technical Prediction
FAILURE (statistically insignificant additive clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
313 days in advance
Readout Data Interpretation
tiragolumab failed to achieve additive clinical benefit in OS
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of Tiragolumab, an Anti-Tigit Antibody, in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer
Phase
Phase 3
Status
Completed
Enrollment
620
Lead sponsor
Hoffmann-La Roche
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG: Atezolizumab; DRUG: Tiragolumab; DRUG: Matching Placebo
Design
Randomized · Parallel · Triple
Primary purpose
Treatment
Start
2020-03-04
Primary completion
2025-12-30
Completion
2025-12-30
Primary outcomes
  • Investigator-Assessed Progression-Free Survival (PFS) in the Primary Analysis Set (From randomization to the first occurrence of disease progression or death from any cause, whichever occurs first (up to approximately 59 months))
  • Overall Survival (OS) in the Primary Analysis Set (From randomization to death from any cause (up to approximately 59 months))
  • Percentage of Participants With Adverse Events (AEs) (Up to approximately 59 months)
  • Percentage of Participants With Cytokine-Release Syndrome (CRS) (Up to approximately 59 months)

NCT04294810 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials